Bausch Health Cos (NYSE:BHC) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Bausch Health Cos (NYSE:BHC) to a hold rating in a research note published on Monday,Zacks.com reports.

Several other research firms have also recently weighed in on BHC. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bausch Health Cos in a research note on Monday. Barclays began coverage on Bausch Health Cos in a research report on Monday, December 8th. They issued an “equal weight” rating and a $8.00 price objective for the company. Finally, Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Five investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, Bausch Health Cos presently has an average rating of “Hold” and an average price target of $8.67.

Bausch Health Cos Price Performance

Shares of Bausch Health Cos stock opened at $6.81 on Monday. The company has a debt-to-equity ratio of 57.48, a current ratio of 1.30 and a quick ratio of 0.97. The company has a market cap of $2.52 billion, a PE ratio of 7.02 and a beta of 0.41. The firm has a fifty day moving average price of $6.50 and a two-hundred day moving average price of $6.53. Bausch Health Cos has a fifty-two week low of $4.25 and a fifty-two week high of $8.69.

Institutional Investors Weigh In On Bausch Health Cos

Several large investors have recently modified their holdings of BHC. Vanguard Group Inc. raised its holdings in shares of Bausch Health Cos by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company’s stock worth $76,152,000 after buying an additional 61,621 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Bausch Health Cos by 4.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,341,999 shares of the company’s stock valued at $8,700,000 after acquiring an additional 57,963 shares during the period. Nuveen LLC acquired a new position in Bausch Health Cos during the first quarter worth $1,473,000. Northwest & Ethical Investments L.P. lifted its holdings in shares of Bausch Health Cos by 26.3% during the first quarter. Northwest & Ethical Investments L.P. now owns 89,848 shares of the company’s stock valued at $583,000 after acquiring an additional 18,709 shares during the period. Finally, Quantbot Technologies LP lifted its holdings in shares of Bausch Health Cos by 387.9% during the first quarter. Quantbot Technologies LP now owns 21,235 shares of the company’s stock valued at $137,000 after acquiring an additional 16,883 shares during the period. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.